# Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD

> **NCT02884908** · PHASE3 · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 57 (actual)

## Conditions studied

- PTSD
- Alcohol Use Disorder

## Interventions

- **DRUG:** Pregabalin plus BBCET
- **OTHER:** Placebo plus BBCET

## Key facts

- **NCT ID:** NCT02884908
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-07
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-01-19
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02884908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02884908, "Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02884908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*